Halozyme Therapeutics, Inc.(NASDAQ : HALO)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||0.26%||7.68||0.7%||$536.86m|
|GILD||Gilead Sciences, Inc.||-0.55%||68.53||1.0%||$504.56m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.11%||516.62||2.7%||$432.65m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.09%||173.49||2.0%||$412.31m|
|VRTX||Vertex Pharmaceuticals, Inc.||1.28%||217.09||1.9%||$311.54m|
|CRSP||CRISPR Therapeutics AG||5.58%||106.64||0.6%||$171.41m|
|BNGO||Bionano Genomics, Inc.||22.45%||5.40||0.0%||$162.77m|
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.